Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
July 16, 2013
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer
Toshikazu Moriwaki, Shinji Hirai, Shuichi Hironaka, et al.
Antioxidants & Redox Signaling
|
May 8, 2004
Mitochondrial signal lacking manganese superoxide dismutase failed to prevent cell death by reoxygenation following hypoxia in a human pancreatic cancer cell line, KP4
Futoshi Hirai, Shigeatsu Motoori, Shizuko Kakinuma, et al.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society
|
May 24, 2019
Skill-up study of systemic endoscopic examination technique using narrow band imaging of the head and neck region of patients with esophageal squamous cell carcinoma: Prospective multicenter study
Naoki Okamoto, Hiroyuki Morimoto, Yoichi Yamamoto, et al.
Cancer Science
|
November 16, 2022
Derivation of pancreatic acinar cell carcinoma cell line HS-1 as a patient-derived tumor organoid
Daisuke Hoshi, Emiri Kita, Yoshiaki Maru, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2017
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Makoto Ueno, Chung Pin Li, Masafumi Ikeda, et al.
Cancer Chemotherapy and Pharmacology
|
December 11, 2013
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Kentaro Sudo, Takeshi Ishihara, Nobuto Hirata, et al.
ESMO Open
|
August 2, 2017
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, et al.
Hepatology International
|
April 13, 2011
Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
Sadahisa Ogasawara, Fumihiko Kanai, Shuntaro Obi, et al.
Cancer Chemotherapy and Pharmacology
|
October 23, 2013
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer
Hiroki Yamaue, Sohei Satoi, Takamasa Kanbe, et al.
World Journal of Gastroenterology
|
February 9, 2016
Diagnostic and therapeutic single-operator cholangiopancreatoscopy in biliopancreatic diseases: Prospective multicenter study in Japan
Toshio Kurihara, Ichiro Yasuda, Hiroyuki Isayama, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
July 16, 2013
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer
Toshikazu Moriwaki, Shinji Hirai, Shuichi Hironaka, et al.
Antioxidants & Redox Signaling
|
May 8, 2004
Mitochondrial signal lacking manganese superoxide dismutase failed to prevent cell death by reoxygenation following hypoxia in a human pancreatic cancer cell line, KP4
Futoshi Hirai, Shigeatsu Motoori, Shizuko Kakinuma, et al.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society
|
May 24, 2019
Skill-up study of systemic endoscopic examination technique using narrow band imaging of the head and neck region of patients with esophageal squamous cell carcinoma: Prospective multicenter study
Naoki Okamoto, Hiroyuki Morimoto, Yoichi Yamamoto, et al.
Cancer Science
|
November 16, 2022
Derivation of pancreatic acinar cell carcinoma cell line HS-1 as a patient-derived tumor organoid
Daisuke Hoshi, Emiri Kita, Yoshiaki Maru, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2017
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Makoto Ueno, Chung Pin Li, Masafumi Ikeda, et al.
Cancer Chemotherapy and Pharmacology
|
December 11, 2013
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Kentaro Sudo, Takeshi Ishihara, Nobuto Hirata, et al.
ESMO Open
|
August 2, 2017
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, et al.
Hepatology International
|
April 13, 2011
Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
Sadahisa Ogasawara, Fumihiko Kanai, Shuntaro Obi, et al.
Cancer Chemotherapy and Pharmacology
|
October 23, 2013
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer
Hiroki Yamaue, Sohei Satoi, Takamasa Kanbe, et al.
World Journal of Gastroenterology
|
February 9, 2016
Diagnostic and therapeutic single-operator cholangiopancreatoscopy in biliopancreatic diseases: Prospective multicenter study in Japan
Toshio Kurihara, Ichiro Yasuda, Hiroyuki Isayama, et al.
Page
of 11